Blinatumomab, a CD19-binding bispecific Ab, and Inotuzumab ozogamicin, an ADC that binds to CD22, received FDA- and EMA- approval for the treatment of relapsed or refractory B-ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.